Literature DB >> 23877634

18F-Fluoride PET/CT in the detection of bone metastases in clear cell renal cell carcinoma: discordance with bone scintigraphy.

Chiara Fuccio1, Elena Giulia Spinapolice, Carla Cavalli, Raffaella Palumbo, Daniela D'Ambrosio, Giuseppe Trifirò.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23877634     DOI: 10.1007/s00259-013-2508-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  3 in total

Review 1.  Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?

Authors:  Daniel Keizman; Maya Ish-Shalom; Natalie Maimon; Maya Gottfried
Journal:  World J Urol       Date:  2013-03-31       Impact factor: 4.226

2.  Skeletal complications and survival in renal cancer patients with bone metastases.

Authors:  Emma Woodward; Satinder Jagdev; Lucy McParland; Katy Clark; Walter Gregory; Alex Newsham; Suzanne Rogerson; Kate Hayward; Peter Selby; Janet Brown
Journal:  Bone       Date:  2010-09-18       Impact factor: 4.398

Review 3.  Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases.

Authors:  Sue Chua; Gopinath Gnanasegaran; Gary J R Cook
Journal:  Semin Nucl Med       Date:  2009-11       Impact factor: 4.446

  3 in total
  2 in total

Review 1.  PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.

Authors:  Kirsten Bouchelouche; Peter L Choyke
Journal:  PET Clin       Date:  2015-04-24

2.  Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.

Authors:  E L Gerety; E M Lawrence; J Wason; H Yan; S Hilborne; J Buscombe; H K Cheow; A S Shaw; N Bird; K Fife; S Heard; D J Lomas; A Matakidou; D Soloviev; T Eisen; F A Gallagher
Journal:  Ann Oncol       Date:  2015-07-22       Impact factor: 32.976

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.